Lindsey Gasparini: New FDA-approved therapy targets Claudin18.2 in gastric cancers
Lindsey Gasparini, Vice President of Biopharma Data Solutions at NeoGenomics Laboratories, shared a post by NeoGenomics Laboratories on LinkedIn, adding the following:
“Let’s talk about Claudin! No longer emerging… Claudin 18.2 is now actionable with a new FDA-approved therapy announced earlier this week. NeoGenomics is a day-one ready lab for testing – which also means we will be generating important new data! This novel target is detected via IHC and looks at membrane staining intensity and percent of positive tumor cells.
With 70% of gastric/GEJ cancers having some form of Claudin18 expression, this is important information for providers, patients, and researchers alike.”
Quoting NeoGenomics Laboratories’ post:
“There is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Claudin18.2 (CLDN18.2) is a new biomarker with a targeted therapy to treat gastric/GEJ cancer and can improve the outcome for patients.
To learn how CLDN18.2 testing can enhance care and help your patients, we invite you to visit us online or call us at 866.776.5907, option 3.
References:
1. https://seer.cancer.gov/statfacts/html/stomach.html
2. https://seer.cancer.gov/statfacts/html/esoph.html
3. https://www.gastriccancerbiomarkers.com“
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023